Chengbiao Lu1, Yun Wei2, Rui Hu2, Yong Wang2, Kun Li2, Xiaoli Li3,4. 1. The Laboratory of Neuronal Network and Brain Disease Modulation, Yangtze University Medical School, Jingzhou, Hubei, China. 2. The Key Laboratory of Industrial Computer Control Engineering of Hebei Province, Institute of Electrical Engineering, Yanshan University, Qinhuangdao, Hebei, China. 3. State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China. 4. Center for Collaboration and Innovation in Brain and Learning Sciences, Beijing Normal University, Beijing, China.
Abstract
PURPOSE: Oxidative stress is involved in the pathological process of Parkinson's disease (PD). The present study was designed to investigate the effects of transcranial direct current stimulation (tDCS) on the oxidative stress in a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). METHODS: The animals were modulated by tDCS. Behavioral alterations were observed after three weeks of tDCS treatment using rotary performance tests. The mice were sacrificed for the measurement of the level of dopamine (DA), enzymatic tyrosine hydroxylase (TH), nonenzymatic malonaldehyde (MDA), an enzymatic superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in the mouse brain and serum. RESULTS: The mice treated with MPTP had an increased MDA level but a decreased SOD and GSH-Px activity, as well as a behavior impairment. These abnormalities were significantly attenuated by tDCS treatment and by levodopa and benserazide. DISCUSSION: The study demonstrated that the tDCS could have a potential for the therapeutic usage in the PD.
PURPOSE: Oxidative stress is involved in the pathological process of Parkinson's disease (PD). The present study was designed to investigate the effects of transcranial direct current stimulation (tDCS) on the oxidative stress in a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). METHODS: The animals were modulated by tDCS. Behavioral alterations were observed after three weeks of tDCS treatment using rotary performance tests. The mice were sacrificed for the measurement of the level of dopamine (DA), enzymatic tyrosine hydroxylase (TH), nonenzymatic malonaldehyde (MDA), an enzymatic superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in the mouse brain and serum. RESULTS: The mice treated with MPTP had an increased MDA level but a decreased SOD and GSH-Px activity, as well as a behavior impairment. These abnormalities were significantly attenuated by tDCS treatment and by levodopa and benserazide. DISCUSSION: The study demonstrated that the tDCS could have a potential for the therapeutic usage in the PD.
Authors: Benjamin Meyer; Caroline Mann; Manuela Götz; Anna Gerlicher; Victor Saase; Kenneth S L Yuen; Felipe Aedo-Jury; Gabriel Gonzalez-Escamilla; Albrecht Stroh; Raffael Kalisch Journal: J Neurosci Date: 2019-05-01 Impact factor: 6.167
Authors: Aurore Thibaut; Vivian L Shie; Colleen M Ryan; Ross Zafonte; Emily A Ohrtman; Jeffrey C Schneider; Felipe Fregni Journal: Burns Date: 2020-06-20 Impact factor: 2.744